Featured News

As part of our rapidly expanding efforts to secure a clear path for the development of treatments and funding for celiac disease at the federal level, we are pleased to…

We are delighted to report at the beginning of this calendar year two significant milestones in our ongoing efforts to compel the federal government to treat celiac disease with the seriousness it deserves.  

For the first time ever, access for funding for celiac disease research is being made available through the U.S. DOD Congressionally Directed Medical Research Programs (DOD-CDMRP) Peer Review Medical Research Program Listing.

Piecemeal solutions are no longer an option. It is time for a complete transformation of the health care system to promote unbiased structures and processes to advance equitable access to quality health care for all.

2023 promises to be a year full of robust research, advocacy, and education efforts on behalf of our patient community.

The American College of Gastroenterology has updated its guidelines for the diagnosis and management of celiac disease, bringing current the recommendations outlined in 2013.

Consider joining the CeDar Rose Study, a remote celiac disease study that will monitor individual gluten tolerance.

The Celiac Disease Foundation is pleased to announce it will provide patient recruitment and eligibility screening for Anokion’s phase 1b/2 clinical trial for KAN-101.

On October 13, 2022 the Celiac Disease Foundation hosted the Ask-the-FDA Educational Webinar with representatives from the U.S. Food and Drug Administration and Coeliac UK.

The Celiac Disease Foundation announces its newest appointee, William Thurston, to its Board of Directors.